Supernus Pharmaceuticals Inc
F:S49
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Supernus Pharmaceuticals Inc
F:S49
|
US |
|
S
|
Sturm Ruger & Company Inc
F:ST2
|
US |
|
SB Financial Group Inc
F:9KH
|
US |
|
First Business Financial Services Inc
F:45D
|
US |
|
Nurexone Biologic Inc
F:J90
|
CA |
|
O
|
OFS Capital Corp
F:9UD
|
US |
|
Reliance Steel & Aluminum Co
NYSE:RS
|
US |
|
S
|
Sumitomo Rubber Industries Ltd
F:108
|
JP |
|
T
|
Telefonaktiebolaget LM Ericsson
XMUN:ERCB
|
SE |
|
Arcticzymes Technologies ASA
F:B4V
|
NO |
|
Greenwich Lifesciences Inc
NASDAQ:GLSI
|
US |
|
S
|
Stewart Information Services Corp
F:SIU
|
US |
|
P
|
Pebblebrook Hotel Trust
F:PD0
|
US |
|
T
|
Terreno Realty Corp
F:T37
|
US |
|
Grenevia SA
F:8MF
|
PL |
|
L
|
L'Air Liquide Societe Anonyme pour l'Etude et l'Exploitation des Procedes Georges Claude SA
F:AILA
|
FR |
|
S
|
Seabridge Gold Inc
XMUN:SRM
|
CA |
|
M
|
MHP Hotel AG
XMUN:CDZ0
|
DE |
|
Dream Impact Trust
F:6470
|
CA |
Wall St Price Targets
S49 Price Targets Summary
Supernus Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for S49 is 61.35 EUR with a low forecast of 53.18 EUR and a high forecast of 66.34 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is S49's stock price target?
Price Target
61.35
EUR
According to Wall Street analysts, the average 1-year price target for S49 is 61.35 EUR with a low forecast of 53.18 EUR and a high forecast of 66.34 EUR.
What is the Revenue forecast for Supernus Pharmaceuticals Inc?
Projected CAGR
8%
Over the last 13 years, the compound annual growth rate for Revenue has been 61%. The projected CAGR for the next 8 years is 8%.
What is the Gross Profit forecast for Supernus Pharmaceuticals Inc?
Projected CAGR
7%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 59%. The projected CAGR for the next 8 years is 7%.
What is the Operating Income forecast for Supernus Pharmaceuticals Inc?
Projected CAGR
61%
The compound annual growth rate for Operating Income over the next 8 years is 61%.
